The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in serious chaos all over the world. In addition to the available vaccines, the development of treatments to cure COVID-19 should be done quickly. One of the fastest strategies is to use a drug-repurposing approach. To provide COVID-19 patients with useful information about medicines currently being used in clinical trials, twenty-four compounds, including antiviral agents, were selected and assayed. These compounds were applied to verify the inhibitory activity for the protein function of 3CLpros (main proteases) of SARS-CoV and SARS-CoV-2. Among them, viral reverse-transcriptase inhibitors abacavir and tenofovir revealed a good inhibitory effect on both 3CLpros. Intriguingly, sildenafil, a cGMP-specific phosphodiesterase type 5 inhibitor also showed significant inhibitory function against them. The in silico docking study suggests that the active-site residues located in the S1 and S2 sites play key roles in the interactions with the inhibitors. The result indicates that 3CLpros are promising targets to cope with SAR-CoV-2 and its variants. The information can be helpful to design treatments to cure patients with COVID-19.
【저자키워드】 Drug repurposing, Antiviral, SARS-CoV-2 3CL protease, FRET, inhibitory compounds, 【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, coronavirus, SAR-CoV-2, Vaccines, SARS-CoV, clinical trials, 3CLpro, in silico, inhibitors, variants, Medicine, Protein, outbreak, Antiviral agents, target, Proteases, inhibitor, information, compounds, docking study, Interaction, COVID-19 patient, acute respiratory syndrome, residue, Compound, inhibitory effect, inhibitory activity, inhibitory, approach, selected, S1 and S2, caused, addition, applied, indicate, patients with COVID-19, 【제목키워드】 SARS-CoV-2, 3CLpro, target, against SARS-CoV,